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ORIGINAL ARTICLE
Tumor-Infiltrating Foxp3 Regulatory T Cells are
Correlated with Cyclooxygenase-2 Expression and are
Associated with Recurrence in Resected Non-small Cell
Lung Cancer
Katsuhiko Shimizu, MD, PhD, Masao Nakata, MD, PhD, Yuji Hirami, MD, PhD,
Takuro Yukawa, MD, Ai Maeda, MD, and Kazuo Tanemoto, MD, PhD
Background: Cyclooxygenase-2 (COX-2) is constitutively overex-
pressed in a variety of epithelial malignancies and is usually asso-
ciated with a poor prognosis. COX-2-derived prostaglandin E2
transforms CD4CD25 T regulatory (Treg) cells (Tregs), and
Tregs are thought to moderate the antitumor immune response.
Herein, we investigated the prognostic value of tumor-infiltrating
Treg cells and their correlation with COX-2 expression in resected
non-small cell lung cancer (NSCLC).
Material and Methods: Intratumoral COX-2 and Treg expression
were retrospectively assessed using immunohistochemistry in par-
affin-embedded samples from 100 patients who had undergone
complete resections for NSCLC. The expressions of COX-2 and
Foxp3, which was most specific Treg cell marker, were compared
with the clinicopathological variables, and the correlation between
Foxp3 Tregs and COX-2 expression was analyzed.
Results: The recurrence-free survival (RFS) of patients with ele-
vated COX-2 expression was significantly worse than that of pa-
tients without COX-2 expression. Tumor-infiltrating Foxp3-positive
lymphocytes were positively correlated with COX-2 expression. The
median count for Foxp3-positive lymphocytes was 3 (minimum-
maximum, 0–24) in 10 high-power fields. The RFS of patients with
tumors containing 3 Foxp3-positive cells (Foxp3 expression
group) was significantly worse than that of patients with tumors
containing 3 Foxp3-positive cells. In a multivariate analysis, only
nodal status was an independent predictor of a significantly shorter
RFS. However, in node-negative NSCLC, Foxp3 expression was an
independent predictor of a significantly shorter RFS.
Conclusions: Tumor-infiltrating Foxp3 Tregs were positively cor-
related with intratumoral COX-2 expression and were associated
with a worse RFS, especially among patients with node-negative
NSCLC.
Key Words: Foxp3, Regulatory T cell, Cyclooxygenese-2, Non-
small cell lung cancer.
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Lung cancer is a major cause of death in many developedcountries. Surgical resection continues to play an impor-
tant role in the treatment of this disease, especially during the
early stages of lung cancer. Even when patients are diagnosed
at an early stage, however, the relapse rate is high as 15 to
35% after surgical resection in Japan.1 Despite having iden-
tical radiologic and histologic features, many patients with
presumed localized disease also have undetectable metastases
at the time of diagnosis. Thus, the current clinical-pathologic
staging system is inadequate.
Cyclooxygenase (COX) is the key enzyme required for
the conversion of arachidonic acid to prostaglandins (PGs).
Two COX isoforms have been identified and are referred to
as constitutive COX (COX-1) and inducible COX (COX-2),2
COX-1 is constitutively expressed in many tissues and plays
an important role in the control of homeostasis. Conversely,
COX-2 is an inducible enzyme that is activated in response to
extracellular stimuli such as growth factors and proinflam-
matory cytokines.3 Some investigators have demonstrated
that COX-2 is constitutively overexpressed in a variety of
epithelial malignancies such as lung, breast, pancreas, colon,
esophagus, and head and neck cancers, and COX-2 overex-
pression is usually associated with a poor prognosis.4–9
T regulatory (Treg) cells (Tregs) were initially charac-
terized as having a CD4CD25 phenotype, and these cells
are thought to modulate the antitumor immune response.10
Tregs can suppress the activity of cytotoxic T cells through
direct cell-to-cell contact or through the release of cytokines.
The most specific Treg cell marker identified to date is a
nuclear transcription factor known as Foxp3.11,12 A high
density of tumor-infiltrating Foxp3 Tregs is reportedly
associated with a higher risk of recurrence and a poor overall
survival among patients with certain types of malignant
neoplasms.13–18 Thus, Treg cells within the tumor microen-
vironment might play a significant role in the suppression of
local antitumor immune responses.
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A recent report has shown that tumor-derived COX-2/
PGE2 induces the expression of the Foxp3 gene and increases
Treg cell activity in lung cancer.19 In this study, we investi-
gated the prognostic value of intratumoral COX-2 expression
and tumor-infiltrating Foxp3 Tregs and determined whether
a correlation exists between the expression of COX-2 and
Foxp3 Tregs in non-small cell lung cancer (NSCLC).
PATIENTS AND METHODS
Study Population
One hundred patients with NSCLC who underwent
resection at our institution were retrospectively studied. All
the patients had undergone a lobectomy and lymph node
dissection and had followed up for at least 2 years. Patients
who had received induction therapy or who had another
malignancy were excluded. The baseline demographics, his-
topathologic data, RFS period, and pathologic specimens
preserved in paraffin were available for all the patients. A
written informed consent was obtained from each patient
before surgery, and this study was approved by the institu-
tional Ethics Committee of Kawasaki Medical School.
Immunohistochemistry
Immunohistochemical analyses were performed using
resected, paraffin-embedded lung cancer tissues. After mic-
rotome sectioning (4 m), the slides were processed for
COX-2 and Foxp3 staining using an automated immunos-
tainer (Nexes; Ventana, Tucson, AZ). The streptavidin-
biotin-peroxidase detection technique using diaminobenzi-
dine as a chromogen was applied. The primary antibodies
were used according to the manufacturer’s instructions
(COX-2: DakoCytomation clone CX-294, 1/50 dilution;
Foxp3: Abcam, clone 22510, 1/100 dilution).
The slides were examined by an investigator who had
no knowledge of the corresponding clinicopathologic data.
To evaluate the COX-2 immunostaining, the reactions in
smooth muscles and vascular endothelial cells, which were
present in all the specimens, were used as internal built-in
controls. Cases with tumor cells that exhibited a significantly
more intense staining pattern than an internal control cells
were recorded as positive20 (Figure 1A). To evaluate Foxp3
immunostaining, 10 high-power fields (HPFs) digital images
of the tumor areas were selected, and the absolute number of
Foxp3-positive lymphocytes in these 10 HPF digital images
was determined. The number of immunostained Foxp3 cells
was then determined by averaging the 10 HPF digital image
cell counts14 (Figure 1B).
Statistical Analysis
Given that there are no widely accepted standard cutoff
points for defining clinical outcome according to the number
of Tregs in the present setting and consistent with the method
used in previous studies, we selected the median intratumor
Foxp3 T cell count of the entire group as the cutoff value.
We then assessed the associations among COX-2 expression,
Treg number, clinicopathologic features, and RFS. The fol-
lowing patient characteristics were investigated: age, sex,
histology, tumor size, and nodal involvement of lung cancers.
A statistical analysis examining significant differences among
the categorized groups and possible correlations between
COX-2 expression and the clinicopathologic features were
performed using the Fisher’s exact test or the 2 test, as
appropriate. An unpaired t test was used for the comparison
of continuous data. Multivariate analyses were performed
using a logistic regression analysis. To explore the associa-
tion between RFS and COX-2 expression or the Foxp3
Treg count, a Kaplan-Meier survival analysis was performed
by stratifying significant predictor variables identified in the
Cox proportional hazards model. All data were analyzed
using the Stat View software program, version 5.0 (SAS
Institute Inc., Cary, NC). All statistical tests were two -sided,
and probability values 0.05 were regarded as statistically
significant.
RESULTS
The patient characteristics and immunohistochemical
variables are shown in Table 1. The tumors were staged
according to the 1997 tumor, node, metastasis staging system.
Relation between the Expression Status of
COX-2 and Clinicopathologic Characteristics
Of the 100 patients, 65 exhibited markedly more in-
tense COX-2 immunoreactivities in their tumor cells,
whereas the remaining 35 cases did not show an increase in
COX-2 expression. A significant association between ele-
vated COX-2 expression and nodal involvement was ob-
served (p  0.033), but no significant associations with age
(p  0.212), sex (p  0.285), histology (p  0.129), tumor
size (p  0.739), or disease stage (p  0.130) were noted
(Table 1). The RFS of patients with elevated COX-2 expres-
FIGURE 1. Immunohistochemical
staining for COX-2 (A) and Foxp3 (B).
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sion was significantly worse than that of patients without
COX-2 expression (p  0.017 according to a log-rank test;
Figure 2).
Relation between the Expression Status of
COX-2 and the Foxp3-Positive Lymphocyte
Count
In the COX-2 positive group, the mean Foxp3-positive
lymphocyte count of 10 HPF was 6.5  5.5. Conversely, in
the COX-2 negative group, the mean Foxp3-positive lympho-
cyte count of 10 HPF was 1.7  1.5. Tumor-infiltrating
Foxp3-positive lymphocytes were positively correlated with
COX-2 expression (p  0.001) (Figure 3).
Relation between the Expression Status of
Foxp3 and Clinicopathologic Characteristics
Among the 100 cases, the median count of Foxp3-
positive lymphocytes was 3 (minimum-maximum, 0–24).
The number of cases with Foxp3 cells 3 and the number
with 3 (Foxp3 expression group) were 49 and 51, respec-
tively. No significant associations between an elevation in
Foxp3 expression and age (p  0.192), sex (p  0.999),
FIGURE 2. Kaplan-Meier recurrence-free survival curve ac-
cording to COX-2 expression, log-rank p  0.017.
FIGURE 3. Relationship between the expression status of
COX-2 and tumor-infiltrating Foxp3 regulatory T-cells,
*p  0.001.
TABLE 1. The Patient Characteristics by COX-2 and Foxp3
Characteristics
COX-2 Expression Foxp3-Positive Cells
Positive Negative p >3 <3 p
Patients, number 65 35 51 49
Age (yr) 68  11 66  9 0.212 69  10 67  10 0.192
Gender
Male 42 18 0.285 31 29 0.999
Female 23 17 20 20
Histology
Adenocarcinoma 41 28 0.129 33 36 0.465
Squamous cell carcinoma 24 7 18 13
Primary tumor (pT)
T1 31 18 0.739 25 24 0.844
T2 25 14 19 20
T3–4 9 3 7 5
Nodal involvement (pN)
N0 43 31 0.033 34 40 0.081
N1 9 3 6 6
N2 13 1 11 3
Disease stage
IA 23 16 0.130 18 21 0.255
IB 16 13 13 16
II(AB) 11 3 7 7
III(AB) 15 3 13 5
COX, cyclooxygenese-2.
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histology (p 0.465), tumor size (p 0.844), nodal involve-
ment (p  0.081), or disease stage (p  0.255) were noted
(Table 1). The RFS of patients with tumors containing 3
Foxp3 cells (Foxp3 expression group) was significantly
worse than that of patients with tumors containing 3 Foxp3
cells (p  0.004 according to a log-rank test; Figure 4).
Prognostic Value of COX-2 and Tregs
A univariate analysis revealed that nodal status (p 
0.001), COX-2 expression (p 0.017), and Foxp3 expression
(p  0.004) were independent risk factors associated with
RFS. Nevertheless, a multivariate analysis revealed that only
nodal status was an independent risk factor (p  0.004) and
that COX-2 expression (p  0.320), and Foxp3 expression
(p  0.107) were not independent risk factors (Table 2). In
the node-negative group (N  76), the RFS of patients with
elevated COX-2 and Foxp3 expression levels was signifi-
cantly worse than that of patients without COX-2 expression
(p 0.024) or without Foxp3 expression (p 0.001) (Figure
5). Conversely, in the node-positive NSCLC group, the RFS
of patients elevated COX-2 and Foxp3 expression levels was
not significantly worse than that of patients without COX-2
expression (p  0.933) or without Foxp3 expression (p 
0.668). A multivariate analysis revealed that only Foxp3
expression was an independent predictor of RFS (p  0.016)
(Table 2).
DISCUSSION
Previous reports have shown that the total number of
tumor-infiltrating lymphocytes (TILs) is positively associated
with patient prognosis in lung cancer and other cancers.21–23
However, whether all TILs have an antitumor effect is un-
clear. In 2001, Woo et al.24 showed that large populations of
CD4CD25 T cells were present among the TILs of
patients with NSCLC. They demonstrated that CD4CD25
T cells selectively inhibit the host immune response and
therefore could contribute to the progression of lung cancer.25
Since then, malignancies such as lung cancer have also been
noted to have increased numbers of Treg cells and Treg
activity levels within the peripheral blood and within TIL
populations.26–29 In addition, a high density of tumor-infil-
trating Foxp3 Tregs is reportedly associated with a higher
risk of recurrence and a poor overall survival in patients with
stage I NSCLC.13 Our studies also showed that the number of
tumor-infiltrating Foxp3 Tregs was associated with a worse
RFS, especially among patients with node-negative NSCLC.
Meanwhile, a report published nearly a decade ago
showed that COX-2 overexpression was associated with a
poor prognosis and a short survival period in NSCLC.4 To
date, several investigators have intensively studied the con-
tribution of COX-2 to tumorigenesis. Several mechanisms are
thought to mediate the tumorigenic activity of COX-2 as
follows: (1) PGs directly stimulate the proliferation of cancer
cells30,31; (2) COX-2 acts as an angiogenic stimulator and has
been shown to increase the production of angiogenic factors
and the migration of endothelial cells32,33; (3) COX-2-derived
PGs function to prevent apoptosis induced by anticancer
drugs34,35; (4) COX-2 expression might increase the invasive
ability of tumor cells, promoting cancer metastasis36; and (5)
PGs are immunoregulatory molecules that can suppress an-
titumor activity.37,38 Our studies also showed that COX-2
expression was associated with a worse RFS.
Of note, the number of tumor-infiltrating Foxp3
Tregs was positively correlated with intratumoral COX-2
expression in this study. To our knowledge, only one other
report has shown that the number of Tregs is positively
correlated with intratumoral COX-2 expression. Li et al.39
FIGURE 4. Kaplan-Meier recurrence-free survival curve ac-
cording to Foxp3 expression, log-rank p  0.004.
TABLE 2. Prognostic Value of Recurrence-Free Survival
Variables
Univariate Analysis Multivariate Analysis
Unfavorable/Favorable p HR (95% CI) p
All cases
Nodal involvement N1–2/N0 0.001 2.89 (1.40–5.98) 0.004
COX-2 expression Positive/negative 0.017 1.64 (0.62–4.37) 0.320
Foxp3 expression 3/3 0.004 2.02 (0.86–4.74) 0.107
Node-negative cases
COX-2 expression Positive/negative 0.024 1.92 (0.50–7.39) 0.344
Foxp3 expression 3/3 0.001 5.38 (1.38–21.07) 0.016
HR, hazard ratio; CI, confidence interval.
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demonstrated that an increase in the number of peritumoral
Tregs was associated with a worse prognosis and was posi-
tively correlated with intratumoral COX-2 expression in pa-
tients with renal cell carcinoma. Our results using tissues
from patients with NSCLC are similar to this previous report
examining renal cell carcinoma and represent the first report
of these phenomena in NSCLC.
A recent study reported that tumor-induced Treg cell
activity can be downregulated by COX-2 inhibition, leading
to the restoration of antitumor responses. Shama et al.19
documented a COX-2-dependent immunosuppressive net-
work in the NSCLC microenvironment in mice, and tumor-
derived COX-2/PGE2 induced the expression of the Treg
cell-specific transcription factor Foxp3, resulting in an in-
crease in Treg cell activity. In addition, they documented that
COX-2/PGE2 suppressed antigen presentation, decreases
maturation of dendritic cells and potently induced IL-10
transcription while reducing IL-12.40 Baratelli et al.41 re-
ported that PGE2 is involved in the modulation of T cell
function and differentiation in vitro, and an increase in T cell
function and differentiation could contribute to tumor-in-
duced immunosuppression. Mahic et al.42 also described Treg
cells expressed COX-2 and Foxp3 in vitro, and Treg cells
produced PGE2 and suppressed effector T cell responses in a
manner that is reversed by COX-2 inhibitors and PGE2
receptor-specific antagonist. Recently, they described that
Treg cells expressed cell surface markers consistent with
activated phenotype and secreted high levels of TGF-ß and
IL-10 excluding PGE2.43 Our present study using resected
tissue supported these basic experiments, confirming a cor-
relation between Tregs and COX-2 expression in NSCLC.
Future cancer treatments targeting both the control of COX-2
and Treg might be feasible. In fact, recent clinical trial by
Cancer and Leukemia Group B demonstrated that patients
with increased COX-2 expression receiving COX-2 inhibitor
had better survival than did COX-2-expressing patients not
receiving drug.44
In summary, the present results indicate that the num-
ber of tumor-infiltrating Foxp3 Tregs is positively corre-
lated with intratumoral COX-2 expression. Among patients
with node-negative NSCLC, in particular, Foxp3 expression
(tumors containing 3 Foxp3 positive cells in 10 HPFs) was
an independent prognostic factor in a multivariate analysis.
Thus, COX-2 expression might suppress antitumor activity
by tumor-infiltrating Tregs. A COX-2 inhibitor might be
beneficial for the treatment of patients with COX-2 overex-
pression. Further studies examining other types of cancer are
necessary.
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